A Agilent Technologies Inc.

Agilent Inspires at SLAS2023, Highlighting Innovative Automated Workflow Solutions

(NYSE: A) announced today that it will highlight a suite of automated laboratory workflow solutions at the held February 25 through March 1 in San Diego. Agilent is also honored to receive an SLAS designation, signifying going beyond automated instrumentation and bringing complete integrated automated workflow solutions to the lab. Agilent is a leader in advancing automation solutions to help customers improve efficiency and reproducibility across their entire pipeline, from research and drug discovery to development and manufacturing processes.

There is growing pressure on labs to deliver high-quality results while streamlining operations, reducing costs, and increasing revenue. Agilent’s modular automation solutions address a wide array of workflows, including cell analysis, genomics, proteomics, biomolecule analysis, and mass spectrometry in non-regulated and regulated environments. Automating processes and workflows allows scientists and lab technicians to use their time more effectively and focus on higher-value, more productive tasks. Automated sample preparation is streamlined, more accurate, enhances reproducibility, and ultimately enables more confident decisions.

SLAS attendees are invited to visit exhibit booth #1811 and learn more about Agilent’s complete automation portfolio, including these innovations:

  • – Enables the Agilent Bravo NGS to provide thermal cycling as part of a high-throughput automated protocol and extends walkaway time during sample preparation.
  • with the – Provides compact, ease-of-use walkaway automation for NGS library prep and enrichment, requiring only 15 minutes of hands-on time.
  • – Adds 21 CFR Part 11 compliance-enabling features for automated sample preparation workflows across the biopharma drug development process.
  • – Offers integrated and automated tracking of individual cells for various metrics when coupled with Agilent BioTek High Content Imaging systems.
  • with the – Provides a label-free high-throughput potency assay for the immuno-oncology space and high-throughput viral CPE assay for the vaccine market.

Lars Kristiansen, general manager of Agilent’s Automation Solutions Business, commented, “SLAS is a great opportunity for us to demonstrate how our automation solutions continue to redefine what’s possible through our commitment to creating differentiated workflow solutions to advance automation for our customers with critical product innovations.”

“Agilent’s modular workflow solutions are designed to integrate easily and work together seamlessly to reduce or eliminate the risk of human errors. Agilent’s enables and automates these activities to keep end users focused on their science. We look forward to sharing more information at SLAS this year,” Kristiansen added.

Product tutorials will be held on Monday, February 27, and Tuesday, February 28, and a Solutions Spotlight session on Tuesday, February 28, entitled An integrated live-cell imaging system for automated high-throughput analysis of 2D cell migration and chemotaxis. To learn more about these educational events, visit Agilent booth #1811. Agilent is proud to be a diamond sponsor of SLAS2023.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on , and .

EN
22/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch